drug · small molecule
etripamil
Marketedupdated 3mo agoby $MIST Milestone Pharmaceuticals Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for cardiovascular disease and 3 investigational indications.
indications
investigational
Atrial Fibrillation
all catalysts(0)
nothing on the calendar yet
Trials studying etripamil
- phase3Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
- phase3Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
- phase2ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
- phase3Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
- phase3Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 19, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jul 15, 2042method-of-use (U-4370)US 12257224
- Apr 13, 2036formulationUS 10117848
- Jun 19, 2028method-of-use (U-38)US 100105221.8y
- Jun 19, 2028compositionUS 100105231.8y
- Jun 19, 2028formulationUS 92279181.8y
- Jun 19, 2028method-of-use (U-4370)US 94631791.8y
FDA exclusivities (1)
- Dec 12, 2030NCENew Chemical Entity (5y)4.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that